Cargando…

LINC00973 Induces Proliferation Arrest of Drug-Treated Cancer Cells by Preventing p21 Degradation

Overcoming drug resistance of cancer cells is the major challenge in molecular oncology. Here, we demonstrate that long non-coding RNA LINC00973 is up-regulated in normal and cancer cells of different origins upon treatment with different chemotherapeutics. Bioinformatics analysis shows that this is...

Descripción completa

Detalles Bibliográficos
Autores principales: Karpov, Dmitry S., Spirin, Pavel V., Zheltukhin, Andrey O., Tutyaeva, Vera V., Zinovieva, Olga L., Grineva, Evgenia N., Matrosova, Vera A., Krasnov, George S., Snezhkina, Anastasiya V., Kudryavtseva, Anna V., Prassolov, Vladimir S., Mashkova, Tamara D., Lisitsyn, Nikolai A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664178/
https://www.ncbi.nlm.nih.gov/pubmed/33171937
http://dx.doi.org/10.3390/ijms21218322
Descripción
Sumario:Overcoming drug resistance of cancer cells is the major challenge in molecular oncology. Here, we demonstrate that long non-coding RNA LINC00973 is up-regulated in normal and cancer cells of different origins upon treatment with different chemotherapeutics. Bioinformatics analysis shows that this is a consequence of DNA damage response pathway activation or mitotic arrest. Knockdown of LINC0973 decreases p21 levels, activates cellular proliferation of cancer cells, and suppresses apoptosis of drug-treated cells. We have found that LINC00973 strongly increases p21 protein content, possibly by blocking its degradation. Besides, we have found that ectopic over-expression of LINC00973 inhibits formation of the pro-survival p53-Ser15-P isoform, which preserves chromosome integrity. These results might open a new approach to the development of more efficient anti-cancer drugs.